Oxytocin for labour and caesarean delivery: Implications for the anaesthesiologist

Current Opinion in Anaesthesiology

Volumn 24, Issue 3, 2011, Pages 255-261

  Dyer, Robert A ^a   Butwick, Alexander J ^b   Carvalho, Brendan ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Oxytocin; Postpartum haemorrhage; Uterine atony

Indexed keywords

OXYTOCIN; OXYTOCIN RECEPTOR;

ANESTHESIST; ARTICLE; BOLUS INJECTION; CARDIOVASCULAR DISEASE; CESAREAN SECTION; CONTINUOUS INFUSION; DRUG SAFETY; HEART MUSCLE ISCHEMIA; HEMODYNAMIC MONITORING; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INFUSION RATE; LABOR; OBSTETRIC ANESTHESIA; POSTPARTUM HEMORRHAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; TACHYCARDIA; UTERINE ATONY; VAGINAL DELIVERY;

ADULT; ANESTHESIA; CESAREAN SECTION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LABOR, OBSTETRIC; OXYTOCICS; OXYTOCIN; POSTPARTUM HEMORRHAGE; PREGNANCY; RECEPTORS, OXYTOCIN; UTERINE CONTRACTION;

EID: 79960091041     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328345331c     Document Type: Article

References (55)

1. World Health Report 2005: Make every mother and child count. World Health Organization; 2005.
2. Callaghan WM, Kuklina EV, Berg CJ. Trends in postpartum hemorrhage: United States, 1994-2006. Am J Obstet Gynecol 2010; 202:353 e1-6.
3. Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B. Prevalence and risk factors of severe obstetric haemorrhage. BJOG 2008; 115:1265-1272.
4. Bateman BT, Berman MF, Riley LE, Leffert LR. The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries. Anesth Analg 2010; 110:1368-1373. This important analysis showed that postpartum haemorrhage remains an important cause of maternal morbidity and mortality, is often unpredictable, and is increasing in frequency in the USA.
5. Knight M, Callaghan WM, Berg C, et al. Trends in postpartum hemorrhage in high resource countries: A review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth 2009; 9:55.
6. Clark SL, Simpson KR, Knox GE, Garite TJ. Oxytocin: New perspectives on an old drug. Am J Obstet Gynecol 2009; 200:35 e1-6. This is an excellent overview of the problems associated with the obstetric use of oxytocin, which has far-reaching consequences for obstetric anaesthesia practice.
7. Gimpl G, Fahrenholz F. The oxytocin receptor system: Structure, function, and regulation. Physiol Rev 2001; 81:629-683. (Pubitemid 32267075)
8. Wray S. Insights into the uterus. Exp Physiol 2007; 92:621-631. (Pubitemid 47024941)
9. Kimura T, Takemura M, Nomura S, et al. Expression of oxytocin receptor in human pregnant myometrium. Endocrinology 1996; 137:780-785. (Pubitemid 26043774)
10. Nakao K, Inoue Y, Okabe K, et al. Oxytocin enhances action potentials in pregnant human myometrium: A study with microelectrodes. Am J Obstet Gynecol 1997; 177:222-228. (Pubitemid 27327338)
11. Adachi S, Oku M. The regulation of oxytocin receptor expression in human myometrial monolayer culture. J Smooth Muscle Res 1995; 31:175-187. (Pubitemid 26035589)
12. Phaneuf S, Asboth G, Carrasco MP, et al. The desensitization of oxytocin receptors in human myometrial cells is accompanied by down-regulation of oxytocin receptor messenger RNA. J Endocrinol 1997; 154:7-18. (Pubitemid 27304342)
13. Phaneuf S, Rodriguez Linares B, et al. Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour. J Reprod Fertil 2000; 120:91-97.
14. Magalhaes JK, Carvalho JC, Parkes RK, et al. Oxytocin pretreatment decreases oxytocin-induced myometrial contractions in pregnant rats in a concentration-dependent but not time-dependent manner. Reprod Sci 2009; 16:501-508. This is an important in-vitro investigation that gives insight into the phenomenon of oxytocin receptor desensitization. This phenomenon may have clinical implications for the obstetric anaesthesiologist.
15. Balki M, Cristian AL, Kingdom J, Carvalho JC. Oxytocin pretreatment of pregnant rat myometrium reduces the efficacy of oxytocin but not of ergonovine maleate or prostaglandin F 2 alpha. Reprod Sci 2010; 17:269-277. This paper suggests that desensitization following oxytocin exposure in rats is specific to the oxytocin receptor.
16. Grotegut CA, Paglia MJ, Johnson LN, et al. Oxytocin exposure during labor among women with postpartum hemorrhage secondary to uterine atony. Am J Obstet Gynecol 2011; 204:56 e1-6. This clinical investigation provides evidence that oxytocin receptor desensitization may have important clinical implications.
17. Tsen LC, Balki M. Oxytocin protocols during cesarean delivery: Time to acknowledge the risk/benefit ratio? Int J Obstet Anesth 2010; 19:243-245.
18. Clark SL, Belfort MA, Dildy GA, Meyers JA. Reducing obstetric litigation through alterations in practice patterns. Obstet Gynecol 2008; 112:1279-1283.
19. Formweb. Oxytocin. Black box warning. Formulary Productions, LLC; 2009.
20. Institute for Safe Medication Practices. ISMP's list of high-alert medications; 2008. www.ismp.org.
21. Cotter AM, Ness A, Tolosa JE. Prophylactic oxytocin for the third stage of labour. Cochrane Database Syst Rev 2001; 4:CD001808.
22. Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. Cochrane Database Syst Rev 2007; 1:CD003249.
23. Winikoff B, Dabash R, Durocher J, et al. Treatment of postpartum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: A double-blind, randomised, noninferiority trial. Lancet 2010; 375:210-216. This landmark study suggests that oxytocin is preferable to misoprostol for the management of postpartum haemorrhage. Misoprostol was associated with more adverse effects but may be an alternative in poorly resourced areas.
24. World Health Organization. Managing complications in pregnancy and childbirth: A guide for midwives and doctors. World Health Organization; 2007.
25. National Collaborating Centre for Women's and Children's Health. Caesarean Section Clinical Guideline. London: RCOG Press; 2004.
26. Sheehan SR, Wedisinghe L, Macleod M, Murphy DJ. Implementation of guidelines on oxytocin use at caesarean section: A survey of practice in Great Britain and Ireland. Eur J Obstet Gynecol Reprod Biol 2010; 148:121-124.
27. Carvalho JC, Balki M, Kingdom J, Windrim R. Oxytocin requirements at elective cesarean delivery: A dose-finding study. Obstet Gynecol 2004; 104:1005-1010. (Pubitemid 40458764)
28. Butwick AJ, Coleman L, Cohen SE, et al. Minimum effective bolus dose of oxytocin during elective Caesarean delivery. Br J Anaesth 2010; 104:338-343. This well-conducted clinical study provides further evidence concerning the therapeutic range of oxytocin when administered during caesarean delivery.
29. Balki M, Ronayne M, Davies S, et al. Minimum oxytocin dose requirement after cesarean delivery for labor arrest. Obstet Gynecol 2006; 107:45-50.
30. Thomas JS, Koh SH, Cooper GM. Haemodynamic effects of oxytocin given as i.v. bolus or infusion on women undergoing Caesarean section. Br J Anaesth 2007; 98:116-119. (Pubitemid 44896761)
31. George RB, McKeen D, Chaplin AC, McLeod L. Up-down determination of the ED90 of oxytocin infusions for the prevention of postpartum uterine atony in parturients undergoing Cesarean delivery. Can J Anaesth 2010; 57:578-582. This study is one of the first to examine optimal infusion rates for the prevention of postpartum haemorrhage during and after caesarean section.
32. Sarna MC, Soni AK, Gomez M, Oriol NE. Intravenous oxytocin in patients undergoing elective cesarean section. Anesth Analg 1997; 84:753-756. (Pubitemid 27147696)
33. King KJ, Douglas MJ, Unger W, et al. Five unit bolus oxytocin at cesarean delivery in women at risk of atony: A randomized, double-blind, controlled trial. Anesth Analg 2010; 111:1460-1466. The authors compared the merits of a bolus plus infusion of oxytocin, with infusion alone, during and after caesarean delivery.
34. Balki M, Dhumne S, Kasodekar S, et al. Oxytocin-ergometrine co-administration does not reduce blood loss at caesarean delivery for labour arrest. BJOG 2008; 115:579-584. (Pubitemid 351357574)
35. Jackson KW Jr, Allbert JR, Schemmer GK, et al. A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage. Am J Obstet Gynecol 2001; 185:873-877. (Pubitemid 32980529)
36. Bergum D, Lonne H, Hakli TF. Oxytocin infusion: Acute hyponatraemia, seizures and coma. Acta Anaesthesiol Scand 2009; 53:826-827.
37. Dansereau J, Joshi AK, Helewa ME, et al. Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol 1999; 180:670-676. (Pubitemid 29149145)
38. Mukaddam-Daher S, Yin YL, Roy J, et al. Negative inotropic and chronotropic effects of oxytocin. Hypertension 2001; 38:292-296. (Pubitemid 34224760)
39. Dyer R, Reed A, van Dyk D, et al. Hemodynamic effects of ephedrine, phenylephrine, and the coadministration of phenylephrine with oxytocin during spinal anesthesia for elective cesarean delivery. Anesthesiology 2009; 111:753-765. The authors describe the use of phenylephrine to obtund the haemodynamic effects of a bolus of oxytocin in healthy parturients during caesarean delivery.
40. Langesaeter E, Rosseland LA, Stubhaug A. Hemodynamic effects of oxytocin during cesarean delivery. Int J Gynecol Obstet 2006; 95:46-47. (Pubitemid 44310666)
41. Dyer RA, Piercy JL, Reed AR, et al. Hemodynamic changes associated with spinal anesthesia for cesarean delivery in severe preeclampsia. Anesthesiology 2008; 108:802-811. (Pubitemid 351589475)
42. Thomas TA, Cooper GM. Maternal deaths from anaesthesia. An extract from Why Mothers Die 1997-1999, the Confidential Enquiries into Maternal Deaths in the United Kingdom. Br J Anaesth 2002; 89:499-508. (Pubitemid 34993983)
43. Langesaeter E, Dragsund M, Rosseland LA. Regional anaesthesia for Caesarean section in women with cardiac disease: A prospective study. Acta Anaesthesiol Scand 2010; 54:46-54. This is the only study describing the beat by beat haemodynamic effects of small doses of oxytocin during caesarean delivery in patients with severe cardiac disease.
44. Dob DP, Yentis SM. Practical management of the parturient with congenital heart disease. Int J Obstet Anesth 2006; 15:137-144.
45. Tamhane P, O'Sullivan G, Reynolds F. Oxytocin in parturients with cardiac disease. Int J Obstet Anesth 2006; 15:332-333. (Pubitemid 44486017)
46. Svanstrom MC, Biber B, Hanes M, et al. Signs of myocardial ischaemia after injection of oxytocin: A randomized double-blind comparison of oxytocin and methylergometrine during Caesarean section. Br J Anaesth 2008; 100:683-689. (Pubitemid 351774375)
47. Jonsson M, Hanson U, Lidell C, Norden-Lindeberg S. ST depression at caesarean section and the relation to oxytocin dose: A randomised controlled trial. BJOG 2010; 117:76-83. This paper provides further evidence for the importance of avoiding large bolus doses of oxytocin during caesarean delivery, namely the potential for myocardial ischaemia.
48. Dogan R, Birdane A, Bilir A, et al. Frequency of electrocardiographic changes indicating myocardial ischemia during elective cesarean delivery with regional and general anesthesia: Detection based on continuous Holter monitoring and serum markers of ischemia. J Clin Anesth 2008; 20:347-351.
49. Abdul-Karim R, Assali NS. Renal function in human pregnancy. V. Effects of oxytocin on renal hemodynamics and water and electrolyte excretion. J Lab Clin Med 1961; 57:522-532.
50. Langesaeter E, Rosseland LA, Stubhaug A. Haemodynamic effects of repeated doses of oxytocin during Caesarean delivery in healthy parturients. Br J Anaesth 2009; 103:260-262.
51. Rath W. Prevention of postpartum haemorrhage with the oxytocin analogue carbetocin. Eur J Obstet Gynecol Reproduct Biol 2009; 147:15-20. This is an instructive review relating to the pharmacology and clinical efficacy of carbetocin.
52. Van Dongen PW, Verbruggen MM, de Groot AN, et al. Ascending dose tolerance study of intramuscular carbetocin administered after normal vaginal birth. Eur J Obstet Gynecol Reprod Biol 1998; 77:181-187. (Pubitemid 28150124)
53. Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum haemorrhage. The Cochrane Database Syst Rev 2007; 3:CD005457.
54. VercauterenM, Palit S, Soetens F, et al. Anaesthesiological considerations on tocolytic and uterotonic therapy in obstetrics. Acta Anaesthesiol Scand 2009; 53:701-709.
55. Sartain JB, Barry JJ, Howat PW, et al. Intravenous oxytocin bolus of 2 units is superior to 5 units during elective Caesarean section. Br J Anaesth 2008; 101:822-826.